Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib with Alemtuzumab in T-PLL
NCT03989466Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacitinib in T-cell prolymphocytic leukemia (T-PLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events up to 2 years. Started Jan 2020; status: completed.
02
Drugs
itacitinib
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT03989466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989466.